ASCO 2026: Tubulis set to present maturing Phase I/IIa data on TUB-040 exatecan ADC in PROC
Tubulis presents updated TUB-040 Phase I/IIa data at ASCO 2026. Here is what the NAPISTAR 1-01 readout means for NaPi2b and ovarian cancer treatment.
Can Byondis turn novel ADC payload chemistry into a real edge in resistant cancers?
Byondis is showcasing two new ADC technology platforms at AACR 2026. Read why antifolate and phosphonate payloads could reshape oncology innovation.
Fortitude Biomedicines enters the degradation race with catalytic ADC platform GLUE-DACTM
Fortitude Biomedicines launches with $13M to develop glue-payload ADCs for autoimmune and cancer treatment. Find out what makes this platform different.
Can Mabwell’s ADC 7MW4911 overcome drug resistance in late-stage GI cancers?
Mabwell begins U.S. trial of novel CDH17-targeting ADC 7MW4911 for resistant GI cancers. Learn what makes this payload and target combination clinically unique.
Will IFx-2.0 and TBS-2025 push TuHURA into the frontline of resistance-focused oncology?
TuHURA Biosciences, Inc. has announced a comprehensive corporate update that includes progress across three of its major immuno-oncology programs. The update covers the company’s lead asset IFx-2.0, currently in a Phase 3 trial in combination with pembrolizumab for advanced Merkel cell carcinoma; the next-stage development of TBS-2025, a VISTA-blocking monoclonal antibody being advanced for relapsed […]